These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35211549)

  • 41. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study.
    Schöffski P; Besse B; Gauler T; de Jonge MJ; Scambia G; Santoro A; Davite C; Jannuzzo MG; Petroccione A; Delord JP
    Ann Oncol; 2015 Mar; 26(3):598-607. PubMed ID: 25488684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
    Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
    Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.
    Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Song Y; Shi Y
    Eur J Clin Pharmacol; 2013 Feb; 69(2):151-9. PubMed ID: 22729611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
    Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
    Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
    [No Abstract]   [Full Text] [Related]  

  • 45. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
    Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
    Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.
    Hansma AH; Broxterman HJ; van der Horst I; Yuana Y; Boven E; Giaccone G; Pinedo HM; Hoekman K
    Ann Oncol; 2005 Oct; 16(10):1695-701. PubMed ID: 16012180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy of NO regimen and NP regimen on advanced non-small cell lung cancer: a prospective randomized trial].
    Gao JF; Zhang XH; Wang J; Rao ZG; Zhu YZ; Ou WL; Zhang BC; Du GZ
    Ai Zheng; 2005 Aug; 24(8):990-3. PubMed ID: 16086879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of a 72-h concurrent continuous infusion of cisplatin and etoposide in advanced non-small-cell lung cancer.
    Saito H; Shimokata K; Yamamoto M; Saka H; Sakai S; Saito H
    Cancer Chemother Pharmacol; 1993; 32(2):134-6. PubMed ID: 8387399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Combination chemotherapy with Taxol and cisplatin for 57 patients with non-small cell lung cancer by intraartery and intravenous infusion].
    Zhao Y; Wang SM; Zhang J
    Ai Zheng; 2002 Dec; 21(12):1365-7. PubMed ID: 12520750
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lee JS; Lee KH; Cho EK; Kim DW; Kim SW; Kim JH; Cho BC; Kang JH; Han JY; Min YJ; Park K
    Lung Cancer; 2018 Aug; 122():234-242. PubMed ID: 30032838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
    Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
    Fang Y; Wang L; Xia GH; Shi MQ
    Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
    Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
    Asian Pac J Cancer Prev; 2011; 12(10):2705-11. PubMed ID: 22320978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effectiveness study of single high-dose cisplatin with fractionated doses cisplatin in first-line therapy for treatment-naive Chinese patients with advanced non-small-cell lung cancer.
    Li X; Zhao X; Abbas M; Wang L; Li C; Liu S; Feng J; Shi M
    Curr Probl Cancer; 2019 Dec; 43(6):100466. PubMed ID: 30777344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
    Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
    Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.